Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.

Name: Αlpha¹ Rigor Record — Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.
Item: Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.
Rating: 100
Author: Αlpha¹

Martin CK, Carmichael OT, Carnell S, Considine RV, Kareken DA, Dydak U, Mattes RD, Scott D, Shcherbinin S, Nishiyama H, Knights A, Urva S, Biernat L, Pratt E, Haupt A, Mintun M, Otero Svaldi D, Milicevic Z, Coskun T

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.5★ (Adequate), 0 critical, 3 high issues for “Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported phase 1 randomized clinical trial of tirzepatide in adults with overweight or obesity. The paper demonstrates strong scientific premise, rigorous design, adequate reporting of biological variables, ethics, key resources, statistics, data availability, and transparency. Minor reporting gaps include lack of explicit reporting guideline adherence, some internal inconsistencies in reported values, and a few copyedit issues.

Both reviewers classified the study as interventional, and this was adopted. The evaluation covered all eight dimensions; several sub-criteria were marked not applicable for a human clinical trial (e.g., replicate distinction, iacuc statement, cell line authentication). The statistics verification recomputed only 4 tests (all consistent); the paper's full statistical analysis was not independently verified. The citation check found no retracted or unresolved references.

9 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior studies on GLP-1 RAs and tirzepatide, noting their effects on ingestive behavior and brain activity, and identifies gaps such as limited measures and lack of brain functioning measurements. The rationale linking the premise to the study's objectives is logical, and the hypothesis follows from the cited evidence. Limitations of prior research (e.g., limited measures, no CNS data) are explicitly addressed as gaps the current study aims to fill.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper clearly establishes its scientific premise by citing prior work on GLP-1 receptor agonists and tirzepatide, providing a logical rationale for the study, and addressing limitations of prior research.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“Previous studies of selective glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) using self-report inventories suggest these therapies affect ingestive behaviors, while functional magnetic resonance imaging (fMRI) studies using food cues show involvement of central nervous system (CNS) mechanisms.”

direct quote[Introduction, paragraph 3]

“However, these studies used limited measures of ingestive behavior and did not collect brain functioning measurements that could inform CNS mechanisms.”